An ‘in­no­cent by­stander’ in the boom­ing biotech in­vestor world is writ­ing a blank check for $100M. Who’s go­ing to cash it?

Sri­ni Akkara­ju’s LinkedIn pro­file de­scribes his work as a “biotech in­vestor (aka in­no­cent by­stander)” with tongue-in-cheek mod­esty. But he’s been deeply steeped in the ways of ven­ture in­vest­ing since leav­ing a BD job at Genen­tech in 2001, fol­low­ing a ca­reer path that wound through New Leaf and Sofinno­va Ven­tures in Men­lo Park. And now he’s ex­e­cut­ing a quick flip on Wall Street for the lat­est in a se­ries of biotech blank check com­pa­nies to de­but this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.